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Introduction: 
G protein-coupled receptors (GPCRs) are the largest family of cell surface receptors. G 
proteins are named after the guanine nucleotide component of the protein, they are also known as 
guanine-nucleotide binding proteins. They are characterized by a heptahelical structure that 
“snake” across a cell membrane. GPCRs have an extracellular N-terminus and an intracellular C-
terminus (Figure 1). The major function of GPCRs is to transmit signals into the cell.  
 
 
These receptors transduce extracellular signals into intracellular biochemical responses. 
GPCRs and proteins associated with GPCRs can function in a several different ways. The 
mediation of receptor signaling is most commonly observed when studying G proteins. A few 
examples of the physiological responses mediated by GPCRs include neurotransmitters, 
hormones, and exogenous sensory stimuli perceived by the senses (i.e. light, odor, and tastes). 
Figure 1. Simplistic representation of GPCR with characteristic seven-
transmembrane helices.1 
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Regulation of receptor signaling is another function of GPCRs and GPCR-associated proteins. 
This regulation happens, by controlling the localization of receptors or by trafficking the receptors 
in a certain way. GPCRs can also be physically linked to a receptor functioning as a scaffold to 
various effectors. They can act as allosteric modulator of receptor conformation, which alters 
receptor pharmacology and other aspects of receptor function. The mechanism of action for 
GPCRs is completed when, molecules called “second messengers” relay the signals received by 
receptors on the cell surface. An example of a signal could be, the arrival of a protein to a target 
molecule in the cytosol or nucleus. Along with their jobs as relay molecules, second messengers 
also serve to amplify the strength of the signal. 
GPCRs are classified into six major families/classes, and if a family is large enough they 
can be further classified into subclasses.2 Class A includes, GPCRs that share similarities with the 
rhodopsin protein, and are commonly known as rhodopsin-like receptors. Rhodopsin-like 
receptors are the largest and best understood family of GPCRs.3 The grouping of GPCRs is 
observed as follows: class A-rhodopsin like, class B-secretin like receptors, class C-
metabotrophic/glutamate/pheromone like receptors, class D-fungal pheromone like receptors, 
class E-cAMP receptor, and class F-frizzled/smoothened like receptors.1,2 Sensing intercellular 
messenger molecules and sensory messages, shows why GPCRs have critical roles in intercellular 
communication.4 Belonging to a family of cell-surface receptors, GPCRs are of pharmacological 
interest because of the numerous physiological processes mediated by GPCRs. Making it possible 
for them to be the targets of several different types of medication. The latest estimate of the number 
of licensed medicinal drugs targeting GPCRs is about 36%.5 This includes hundreds of drug types, 
including: antihistamines, neuroleptics, antidepressants, and antihypertensive.2 Opioid receptors, 
as the name suggests, are another target for drugs, developed for treatment of extreme pain.6 
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GPCRs can also mediate the mechanisms and actions of certain medications, helping to treat 
disorders like drug dependency and mental illness. Studies of GPCRs may greatly assist in the 
process of drug discovery because of the large amounts of drugs targeting GPCRs.5 Understanding 
molecular details of ligand binding is critical for better information regarding receptor function, 
and development of new therapeutic compounds.7  
The exact mechanism of G protein-coupled receptors is complex, and has traditionally been 
thought of as a linear process.8 An agonist, which is a ligand/substance that initiates a physiological 
response when combined with a receptor,9 first binds to the interior of the hydrophobic pockets of 
the extracellular surface (Figure 2).10  
 
 
Figure 2. Illustration of ligand binding in the binding 
pocket of the GPCR3 
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This binding stimulates a conformational change of the GPCR from an inactive to active state.8 
This active state, catalyzes the activation of a guanine binding protein (G protein). It is important 
to note, that an agonist is more likely to choose the receptor with which it has the greatest affinity. 
After activation of the binding protein, comes the activation of the heterotrimeric G protein (G) 
by the phosphorylation of a guanosine diphosphate to guanosine triphosphate. The addition of this 
phosphate, happens within the G subunit and promotes dissociation of G from the G.
8 The 
respective G and G subunits, can now lead to activation or inhibition of effector enzymes and 
ion channels that are able to trigger multiple signaling pathways. These effector enzymes or 
regulating proteins, can either stimulate or inhibit the recruitment/production of secondary 
messengers inside the cell.11 Some examples of second messengers include: cyclic adenosine 
monophosphate (cAMP) and Calcium (Ca2+) ions.  
Ch. 1: GPCR Classes and Activation 
GPCRs make up the biggest family/class of transmembrane receptors in humans.3 Some of 
the larger classes, such as class A (rhodopsin-like), also include subclasses. Each of these classes, 
differ from each other in the way their extracellular binding pocket binds to an agonist or similar 
types of ligands (Figure 3). 
There is a great demand to develop a programable way of determining classes of GPCRs to aid in 
the classification of drugs, but more importantly to improve the process of drug discovery.2 Chou 
succeeded in using a computational method that can determine GPCR family types.2 Using a 
statistical predictor, Chou tried to determine classes and subclasses of GPCRs based on their 
primary amino acid sequence. The amino acid arrangement represents the GPCR sample, and a 
predictor (Covariant Discriminant) is then used to perform the prediction.2 A statistical predictor 
cannot work without a benchmark data set.1 The G-protein coupled receptor database, was used to 
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create this benchmark set.2 To determine the power of the operation engine on the predictor, a 
cross-validation test must be used.  
 
Two different types of cross-validation tests are; the re-substitution test and the jack-knife test. Of 
these two statistical methods, the jack-knife, is thought of as the most exact and unbiased of cross-
validation tests.2 The overall success rate, for identification by the jack-knife test within the data 
set of 1,238 GPCRs was 97.42%. The researcher believes that this accuracy, implies that the 
families of GPCRs are correlated by their amino acid sequence.2 However, the covariant-
discriminant algorithm used in these predictions is still in need of improvement.1  
 A different type of predictor was developed by Brooks et al., in an attempt to improve upon 
the covariant discriminant. It is called the GPCR-Cellular Automaton. This predictor uses cellular 
Figure 3. Schematic showing the difference in six main family classes of GPCRs: a) rhodopsin-like, 
b) secretin- like, c) metabotrophic/glutamate, d) fungal pheromone, e) cAMP receptor, and f) 
frizzled/smoothened family1 
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automaton (CA) images, to find patterns and hidden features in the complex protein composition.1 
There are two levels to this predictor. The first is, to determine if the protein sequence comes from 
a GPCR. The algorithm will then automatically move to the next prediction engine and classify 
which of the six GPCR families the sequence belongs.1 Once again, the G protein coupled receptor 
database was used to create the benchmark data set. However, the pseudo amino acid composition 
is used to represent the protein sample. A set of data from a pseudo amino acid sequence will have 
the 20 known amino acids but will also include a  term. This term, will account for the sequence-
order information, usually lost by using the conventional 20 amino acids.1 The cellular automaton 
images (Figure 4) were analyzed by a new approach called the gray level co-occurrence matrix 
(GLCM). This method, essentially, is able to characterize the texture of an image statistically, at 
different pixels and at different locations.1 Each class of GPCR produces a CA image, with similar 
textures not found in the other families. Thus, a predictor, can determine which textures belong to 
which class of GPCR. The jack-knife test was used to cross-validate the method, and examine the 
usefulness of the predictor.1 The results of the predictor after testing 730 proteins was 91.64% 
(Table 1).  
There are many challenges involved when trying to determine classification or function of 
a GPCR. Due to the costly and time-consuming nature of new NMR and X-ray crystallography 
techniques, it is desirable for a computational method that can efficiently and effectively identify 
functional families of GPCRs. Classifying an unknown sample of GPCR without having to 
determine protein sequence is the main advantage of using cellular automaton images and GLCM 
approach. Brooks et al., have made a web-server that is accessible to the public for free online22, 
it includes the GPCR-CA predictor.1 This predictor could have a major influence on the field of 
pharmacology, by computationally classifying the many GPCRs targeted by therapeutic drugs.  
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Figure 4. Cellular automaton images according to GPCR classes. a) rhodopsin-
like, b) secretin-like, c) metabotrophic/glutamate, d) fungal pheromone, e) cAMP 
receptor, and f) frizzled/smoothened family1 
 
Table 1. Results found using GPCR-CA predictor and jack-knife test for both GPCR and non-
GPCR proteins1 
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The classification of GPCRs is only the beginning when developing new therapeutic drug 
targets. Data about the structure of GPCRs and the details about the states in which they exist, is 
essential to understanding more about how the activation mechanism works. In the past, the 
mystery of why GPCR structure determination was so difficult, is caused by the significant 
conformational plasticity of GPCRs.12 The ability to adopt many different conformations, or 
conformational plasticity, is what makes GPCRs crystallization so complex when trying to 
determine their structure.3 However, improved crystallographic techniques have led to better 
structural studies of GPCRs.3 NMR and electron paramagnetic resonance, along with holo-form 
X-ray crystal structures are also some of the techniques that have made great lengths in 
contributing to the understanding of GPCR signaling.3,4 It is well understood that for activation of 
a GPCR, a conformational change must take place.13 Crystallographic data and other structure 
determining techniques, have led to the conclusion of unique conformation states of GPCRs. As 
the techniques continue to improve, researches will continue to get more accurate structures. This 
is verified by the 42 distinct receptors have been determined.3 The receptors seem to exist in three 
states: active states, active-like states, or inactive states. Active states, are defined as the 
conformation that the receptor takes when it is able to interact with the heterotrimeric G proteins. 
There are many possible types of “active intermediate” states, but they are all steps that are leading 
to active state conformations and allow G-protein interaction. Inactive states, can be identified as 
conformations that have some type of blockage involving their G protein binding surface making 
them unable to interact with G.
3 From studying the structures of different receptor states, 
researchers are able to gather a better understanding of the aspects of GPCR activation.  
Based on the activation mechanism, it is assumed that the lowest energy state of GPCRs is 
in the inactive conformation of the receptor. Support for this generality, are the numerous GPCRs 
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that have been crystallized in the inactive state.3 Active-state structures are difficult to determine 
with agonist binding alone. They have primarily been established with the help of proteins that 
stabilize the active conformation. These proteins are known as GPCR-interacting proteins (GIPs) 
and contain receptor interaction domains that maintain the signaling mechanism.8 G proteins and 
GIPs, are required to stabilize the active state. Proven by agonist bound receptors with the absence 
of G proteins the GPCRs crystallized in the inactive state.10 A strategy, worthy of mention, in the 
complicated process of active-state structure determination is the use of nanobodies.3 Generally, it 
has been determined that agonist binding does increase the tendency for GPCRs to adopt the active 
conformation; however, a bound agonist on its own is not enough to stabilize the active state of 
the receptor.3 Looking carefully at GPCR activation indicates that, for the receptor to 
accommodate binding of the alpha subunit in the heterotrimeric G protein, transmembrane helix 6 
(TM6) must rotate and be displaced (Figure 5). Receptors from other families share similar 
structures in the activated state, including the transmembrane helix 6 rotation. Comparing inactive 
and active state crystal structures for class A receptors, shows the presence of a salt bridge, the 
binding of a sodium ion to an aspartic acid residue stabilizes the inactive state of the receptor.12 
The stabilization of the inactive state is due to this conserved salt bridge or “ionic lock”, and is 
found at the intracellular end of transmembrane 3 (Figure 6).3 It is highly likely that the ionic 
interactions from the salts are what leads to the stability of this state. The ionic lock, is able to 
establish an energy minimum for the inactive conformation. In active receptor conformations, a 
comparable feature to the ionic lock seems to exist, called the “water lock” (Figure 5).  
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Figure 5. Inactive/Active state comparison of acetylcholine receptor. Red arrow 
indicates conformational change upon activation3 
Figure 6. Sodium ion stabilization of inactive state receptor (gray). Water 
lock for active state receptor (orange).3 
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Hydrogen bonds, connecting a transmembrane 7 tyrosine to a transmembrane 5 tyrosine through 
a bridging water molecule.3 The intermolecular forces of the water lock have similar stabilization 
roles to the ionic lock for the active state. Structural sodium ions (S3.39 in Figure 6) can be found 
in most GPCRs connected by amino acid residues of transmembrane 2 and 3 sequences. 
Conformational rearrangement by the receptor when activated breaks the bonds connecting the 
sodium ions. Sodium ions serve as negative allosteric modulators of GPCR activation. They 
decrease agonist affinity and stabilize the inactive state of the receptor.3 
 GPCRs facilitate the physiological responses to a plethora of cellular signals including: 
neurotransmitters, hormones, and sensory stimuli (light, odor, and taste). The transmission of 
signal into the cell completed by GPCRs is crucial to cellular communication. The mechanism that 
mediates this response is complex and involves many parts to ensure completion. The foundation 
of the activation of GPCRs lies in the change in conformation from an inactive to an active state 
upon ligand binding (agonist binding).13 Thanks to the increase of crystal structures identified by 
improved crystallographic and similar techniques, the elements involved in GPCR signaling have 
been made clear. However, questions about GPCR interactions at the cellular level, and the role of 
protein dynamics involving receptors are still controversially debated.4 To answer these questions 
the dynamics of GPCRs must be investigated.  
Ch. 2: GPCR Dynamics and Labeling: 
While crystallography is the primary method for spatial information of GPCRs the receptor 
must be crystallized and cannot exist in solution.5 Owing to their static nature, crystal structures 
offer very little information about the dynamics of conformations in the living cell. Comprehension 
of molecular details involving ligand binding is essential for better discernment of receptor 
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function. More information about the dynamics in vitro will ideally lead to the design and 
development of innovative therapeutic medications.7 In order to monitor ligand-receptor binding 
in living cells some type of labeling of either the receptor or the ligand is needed. Radioactive and 
fluorescent compounds are the best approach to use in this type of situation. There are many 
approaches to using fluorescent/radioactive probes to study ligand-receptor or receptor-receptor 
dynamics. GPCR dynamics studies have required the development of fluorescence energy 
resonance transfer (FRET), radioactive ligand, and time-resolved FRET approaches.8 There are 
advantages and disadvantages of using either radioactive or fluorescent ligands to study ligand-
receptor interactions. 
FRET, one of the more successful approaches using luminescent probes to study ligand or 
receptor-receptor interactions, takes advantage of the energy transfer process of chromophores.8 
As the name suggests, after labeling the GPCR and ligand with specific chromophores (light 
sensitive molecules) a resonance energy transfer process can be engaged, if the chromophores are 
close enough (Figure 7).8 The resonance energy transfer process, diverges from the typical ideas 
of how fluorescence is portrayed. Rather than one molecule absorbing and emitting the energy 
from the radiation, there is an energy transfer between two molecules. The fluorescently tagged 
chromophore on the receptor absorbs the energy from the radiation, and when a fluorescently 
tagged ligand chromophore is close enough, the energy is transferred and emitted by the ligand 
chromophore. Designing a fluorescent GPCR ligand is not a simple process. The binding sites of 
GPCRs are different for each class (Figure 3), and the fluorescently tagged ligands used must 
account for structure activity relationships in order to have a high binding affinity.1,8 The size of 
the fluorophore is an important parameter when choosing ligands.14 This is confirmed by the 
majority of ligands being smaller molecules. When done correctly the fluorescent derivatives are 
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able to maintain high affinities. GPCR fluorescent ligand chemistry, has been advanced by the 
synthesis of low molecular weight organic dyes, with the ability to adjust the fluorescent signaling 
that fits the instrument readout requirements.8  
 
 
Researchers are looking for linkers and dyes that have higher chemical and photostability with 
donors which can lead to multi-wavelength detection. Possible fluorophores for small GPCR 
ligands and peptide ligands are quantum dots, which are an alternative to the classic dyes being 
used. These dots, are fluorescent nanotube semiconductors with possible emission over the visible 
and near infrared range.8 Quantum dots are larger in size, which could be a problem when studying 
membranes in vitro, because they can impede diffusion across the membrane. The synthesis of 
small fluorescent ligands of GPCRs is significant in the FRET approach with many challenges 
Figure 7. Schematic representation of FRET between a fluorescent 
ligand and a corresponding fluorescently tagged receptor8 
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dealing with the affinity and efficacy of the ligand. However, when done properly it helps to further 
our interpretation of ligand receptor interactions of GPCRs in the cell. 
 Another type of compound used for the tagging of GPCR ligands, are radioactive or isotope 
labeled ligands.8 The very existence of adrenergic (class C) receptors on the cell membrane, was 
revealed by using radioactive high-affinity ligands.5 When using radioactive ligands 
(radioligands), a separation of the free ligand and bound ligand is required. The sensitivity of 
studying ligand-receptor interactions, is better in radioactive ligands than in FRET based 
approaches.8 However, while the sensitivity for radioligands is greater than FRET the hazards 
involved in the use and disposal of radioligands makes them less appealing than fluorescent 
approaches.5 The use of fluorescent tracers to visualize GPCRs has advantages over radioactively 
labeled ligands. Fluorescent ligands have easier delivery and disposal of materials, a longer shelf 
life, and shorter signal acquisition times needed to reach an acceptable sensitivity. They can also 
provide instantaneous real time readouts of the ligand-receptor interactions. Overall, radioactive 
ligands are more expensive, time consuming, and difficult to miniaturize or automate.8 Clearly, 
using fluorescent tracers to visualize GPCRs enhances safety and reduces costs.  
 Due to the decreased sensitivity of FRET approaches and the hazards of radioactive 
approaches in ligand-receptor interface studies, researchers investigated ways of improving the 
sensitivity.8 Time-resolved FRET (TR-FRET) has provided a potential solution to the sensitivity 
problem of FRET.5 TR-FRET uses lanthanides, like europium (Eu3+) or terbium (Tb3+) complexed 
with chelates as donor molecules in binding to the ligand. The long-lived emission found in these 
lanthanides allows for separation of the excitation and detection events in the classic FRET 
approach.8 The excellent fluorescent properties of lanthanide complexes make it possible for the 
development of a high throughput screening (HTS), which uses robotics and data processors to 
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conduct millions of chemical, genetic, or pharmacological tests.14 High throughput time-resolved 
FRET assays have been used to scan for drug candidates.5 Generally, time-resolved FRET assays 
has overcome classical FRET approaches largely because of its temporal selectivity and spectral 
affinity.8  
One of the biggest challenges for modern pharmacology is the study of receptor-receptor 
interactions (i.e. GPCR dimerization/oligomerization).8 It is well understood that GPCRs will have 
receptor-receptor interactions in certain environments. The detection of receptor oligomer 
complexes on the plasma membrane of living cells and how oligomerization impact receptor 
function is critical to GPCR pharmacology.8 Fluorescent probes used by FRET have begun a new 
and productive way to study GPCR oligomerization.  
 
 
The method seen in Figure 8, represents the FRET based mechanism of studying GPCR 
oligomerization. This process includes a receptor with a fluorescent tag (FT) in the extracellular 
Figure 8. Schematic representation of FRET-based methods using fluorescent ligands applied 
to the study of GPCR oligomerization on the cell surface of living cells.8  
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region involved in a FRET process with the fluorescent ligand (FL) of the second receptor (R2). 
The receptors forming the oligomer can be detected with FRET fluorescent ligands (FL1 and FL2), 
which after the receptors bind to each other the FRET process is engaged. Interestingly, the 
approach shown in b and c of Figure 8, find ability to detect oligomeric complexes on the plasma 
membrane not only in heterologous systems but also in native tissues.8 This is verified by a study 
with the oxytocin receptor in rats, where europium and another fluorescent ligand tag discovered 
the oligomerization of the receptor in both transfected cells and in the rat’s mammary gland.5  
Receptor visualization is important not only for the development of new drug targets in which 
receptor-receptor interactions are involved, but also in examining GPCR trafficking, functionality, 
and biosynthesis/degredation.8 The possibility that GPCR oligomers have unique targets, opens 
new possibilities for precisely targeting individual pathologies. Chabre et al., has also noted that 
the heterodimerization could upset the pharmacological specificity of the receptors.15 The growth 
and elaboration of new and groundbreaking tools will stimulate many advances in modern 
pharmacology.8 
Another use of fluorescently labeled receptors is in examining the conformational 
dynamics of GPCRs, and is completed by Bockenhauer et al to study the dynamics of 2-
adrenergic receptors from class C.10 The conformational plasticity of GPCRs is very important, 
and has been investigated in many studies involving conformational dynamics or molecular 
dynamics over long time periods.3 Manglik et al, also mention the importance of noting that even 
though receptors fall into classes of active and inactive states, structural data can only represent a 
small percentage of receptor conformations, and that additional states do exist but cannot be 
characterized structurally.3 The researchers under Bockenhauer et al., developed a unique 
apparatus to observe the single labeled adrenergic receptor for a short period of time. This 
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apparatus is called the Anti-Brownian Electrokinetic (ABEL) trap.10 The ABEL trap uses fast 
electrokinetic feedback through a microfluid to excite the fluorescently tagged receptor (Figure 9).  
 
 
Essentially, the ABEL trap combines a fluorescence-based estimation of the target object with fast 
electrokinetic feedback to counter the Brownian motion of the object.16 In a feedback- controlled 
ABEL device, confocal microscopy tracks the position of the molecule from the fluorescent signal, 
and engages feedback-controlled displacement to ensure minimal movement of the molecule. 
Consequently, the ABEL trap works better when trapping smaller objects. After choosing a 
fluorescent dye and labeling the site of ligand binding, a readout of discrete fluorescence intensity 
and lifetime levels in single 2-adrenergic receptors (Figure 10).10 The discrete intensity 
steps/peaks seen in Figure 10 (blue peaks) of ligand free receptor indicate multiple states existence 
for GPCRs. From this data we can 
conclude that GPCRs are extremely dynamic transmembrane proteins that exist in multiple atomic-
scale conformations. Even before an agonist binds to the receptor, they are constantly switching 
between the inactive and active states with many possible intermediate states.10 To further 
understand how agonist binding influences conformational change in GPCRs, Bockenhauer et al. 
used the ABEL trap to study the agonist bound receptors. The data from this experiment can be 
Figure 9. a) Layout of the feedback-controlled ABEL trap, b) top view of trapping cell, c) side view of 
the microfluidic cell.16  
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seen in Figure 11 and illustrates the mean dwell times with ligand free or with agonist bound 
receptors. The conclusions from this graph show that agonist binding does increase the dwell time 
of the active state of the receptor, however, without G-proteins to stabilize the active state the 
receptor will switch back to the inactive conformation.10  
 
 
This is verified by the fact that active state GPCR structures were determined largely with help 
from proteins to stabilize the active conformation.3 Furthermore, in the absence of G-proteins 
agonist bound GPCRs were crystallized in the inactive state.10 
There are many challenges involved in novel drug design and development for modern 
pharmacology. As GPCRs are the target of over 30% of drug screening targets14, data from 
FRET/TR-FRET, radioactive ligands, and conformational dynamics will continue to stimulate 
breakthroughs in the development of novel therapeutic compounds. One thing is certain, the 
development and improvement of innovative and inventive tools will lead to greater progress in 
Figure 10. Graph of intensity-lifetime traces from single trapped ligand free-receptors. Real-time 
intensity (blue) and fluorescence lifetime (green). b,c) correlated intensity, d) uncorrelated, e) 
anticorrelated10 
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the field.10 An understanding of the receptor-ligand binding affinity for possible drug targets is one 
of the largest hurdles for researchers in the drug design field.14 Based on current knowledge of 
GPCRs such as serotonin, 2-adrenergic, or angiotensin indicates that receptor dynamics are 
decisive to understanding their function.17 
 
Figure 11. Histograms of dwell times for ligand free (a) and agonist bound receptors (b).12 
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Ch. 3: Allosteric Modulators 
 When developing any drug, studying the effects of this drug in a system directly, or in 
association with another drug, is the best approach for discovering the mechanism of action of the 
drug.9 Researchers can then compare the responses to a mathematical model of drug-receptor 
interaction. Once the data and the model agree the researchers have found one possible mechanism 
of action for the drug. When the data and the model, do not agree the model can be rejected or 
improved until the mechanism matches the prediction by the model.9 The various physiological 
roles that GPCRs are involved in, and the evidence of signaling in several pathological conditions 
explain why they are the therapeutic target of more than 30% of drugs on the market today.13,18 
Studies of GPCRs have highlighted two sites of possible ligand binding: the orthosteric site and 
the allosteric site (Figure 12).  
 
 
Figure 12. Schematic of the M2-Acetylcholine 
receptor with identified allosteric, orthosteric, and 
G protein sites.19 
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Traditional GPCR drug discovery, has focused on targeting the orthosteric site.12 Endogenous 
ligands, are compounds that are not introduced to the body, but are produced by the body such as:  
neurotransmitters, peptides, hormones, ions, odorants, etc. These ligands are bound at the 
orthosteric site, and are the targets of many therapeutic medications involving GPCRs.12 Allosteric 
modulation of GPCRs by small molecules influencing the effects of endogenous agonists has been 
recognized for a long time.11 The binding of the small sodium ion, established by the comparison 
of inactive and active state crystal structures, has shown allosteric stabilizing tendencies for 
inactive state receptors. When talking about an allosteric modulator they are mainly depicted as, 
any species that is capable of selecting a specific conformation and changing orthosteric ligand 
affinity/efficacy.13 The idea of allosterism was officially accepted with the Monod-Wyman-
Changeux (MWC) model. This model proposes a different mechanism of receptor conformational 
selectivity to account for the action of ligands in the presence of regulatory enzymes.13 The 
mathematical model used in determining the mechanism of action for allosteric modulators can be 
seen in Figure 13. As the numbers of allosteric modulators being tested in humans increases, 
development of more accurate quantitative models, like equation 57, of are needed to decrease the 
rate of failure in new drugs.9  
 
 
Figure 13. Equation 57 describes the effects of an allosteric modulator. B is the direct production of 
receptor response, the  term accounts for altering affinity of the agonist, and  models the efficacy of 
the agonist.9  
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 Potentially all GPCRs contain topographically unique allosteric binding sites, targeting 
these sites presents an opportunity to increase subtype selectivity of drugs.13 Allosteric modulators 
attached to allosteric binding sites of GPCRs provides a conceivable method of drugs with 
differential selectivity and better safety than traditional orthosteric ligands.12 Allosteric modulators 
are not competition with endogenous ligands because they bind to a completely different site on 
the receptor. Traditional drugs that target orthosteric sites completely occupy the site when they 
are bound, causing complete shutoff of a receptor or complete activation of a receptor. Allosteric 
ligands influence receptors at the same as orthosteric ligands. Because they work in a concerted 
fashion, the allosteric ligand is able to regulate receptor activity and prevent the extremes of 
completely shutting off or activating a receptor. This modulation may lead to a decrease in the 
likelihood of side effects.12 Allosteric modulators are also less prone to overdose because of the 
limitations of the modulatory effect.13 One of the proposed solutions of the development of 
tolerance for the well-known analgesic morphine is the lack of ability to internalize the receptor 
caused by the drug. The non-competitive nature of allosteric modulators with ligands bound in the 
orthosteric site, could potentially allow them to induce or prevent receptor internalization that is 
compromised by morphine.13 Two allosteric modulators are currently available to the public with 
FDA approval. Maraviroc20 treats patients with HIV by targeting the chemokine receptor (Figure 
14), and cinacalcet that targets the calcium sensing receptor to treat hyperthyroidism.13 
Despite the approval of these two drugs, the therapeutic relevance of allosteric modulators 
in GPCRs still needs further investigation.13 There are many challenges that involved in the finding 
of allosteric modulators.12 A key part in any drug’s is understanding the effects of drug in an acute 
vs chronic application. Assuming many of these allosteric modulators will be administered 
chronically, a better understanding of receptor regulation pathways is needed.13 Other challenges 
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include low modulator receptor activity, low binding affinities, and the emergence of drug resistant 
mutations to name a few.12 The progress made by crystallography has determined 14 distinct 
allosteric sites12, however, there are hundreds of GPCRs and most of them are yet to be 
crystallized. One solution to the struggle of crystallographic allosteric site determination is the use 
of a computational identifier. Information of the three-dimensional structure of GPCRs is crucial 
to understanding how they function, ligand-receptor binding, and to improve the design and 
development of drugs like allosteric modulators.21 
 
 
Figure 14. Structure of chemokine receptor CCR5 and the 
binding pocket of Maraviroc (purple).20  
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It is important to note that without proper preparation and storage of GPCRs studying the 
function and drug delivery processes is impossible. The trouble of studying membrane proteins 
like GPCRs is how they are located in the plasma membrane.17 Extraction of GPCRs from their 
native environment and stabilizing the proteins by placing them in micelles that mimic the cell 
membrane. The protein is fragile once removed from its native environment and if done improperly 
the integrity of the protein will be compromised. One of the techniques to counter this fragility is 
lyophilization (freeze-drying), where a sample is placed in a vacuum at cryogenic temperatures 
and dehydrated. This method can turn an aqueous solution of proteins into a powder by removing 
water via a sublimation process.17 Freeze-drying eludes the potentially detrimental thawing of the 
proteins because the water is removed from the solution. Applications of these powdered GPCRs 
potentially involve; solid state NMR, studies of receptor signaling, dry powder inhaling, and drug 
design. 
Discussion:  
The amount of physiological regulation that GPCR signals is most likely the reason that 
they are the target of so many therapeutic drugs. They are targeted in many different drugs on the 
market today, for example, antihistamines, antidepressants, and many others. I believe that the 
reason that researchers are so interested in GPCRs is because of the possibilities that they offer. G 
protein coupled receptors are not well enough understood to truly appreciate just how helpful they 
could be in developing unique therapeutic compounds. The difficulty in understanding GPCRs has 
made it harder for researchers to fully understand how they work in the cell.  
 Researchers are trying hard to get as much data as possible about GPCR structure, 
conformations, and interactions on the cell membrane. I believe that only with a combination of 
static structural data and dynamic interaction data will researchers truly be able to develop better 
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drugs. I am convinced that, of the many methods of determining protein three-dimensional 
structure the most valuable regarding GPCRs is X-ray crystallography. Based on number of 
receptors determined, no other technique could match X-ray crystallography. While, the 
computational techniques mentioned in some papers do show promise, but they are lacking to be 
used efficiently unless improved on.   
 Arguably the most important focus of pharmaceutical companies funding research of 
GPCRs should be studies involved ligand-receptor or receptor-receptor interactions in vitro. While 
the crystallographic data is also extremely important; however, I believe that studies involving 
FRET or similar methods are more valuable to drug development. Simply because there is a such 
a risk of not understanding how receptors and ligands behave in cellular conditions. Both structural 
and dynamics data are needed in drug design and improvement, but if deciding where to prioritize 
funding on I would choose the dynamic data over the structural data.  
 Concerning allosteric modulators, I can definitely see the reason why millions of dollars is 
being spent on their research. When they function properly they can alleviate side effects and make 
overdose highly unlikely. However, the problem arises when we consider their binding affinity to 
the receptor. Binding in the allosteric site of GPCRs is not easy. The reason that traditional drug 
techniques target the orthosteric site is because if functions to bind to endogenous ligands. The 
drugs developed hijack this orthosteric site and ensure a high binding affinity. The allosteric site 
of GPCRs functions in a regulative way. It monitors receptor behavior and can control deviations 
with small allosteric ligands that can communicate with the cell. If researchers can find a way to 
ensure allosteric site binding, then their improved safety over traditional orthosteric ligands is 
significant. However, until then I believe pharmaceutical companies will stick with orthosteric 
ligands because they work.   
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Overall, the study of G protein coupled receptors continues to be of major interest for 
modern pharmacology. The impact of GPCRs in cellular communication and other regulatory roles 
they play emphasizes the fundamental biological and clinical importance of this superfamily of 
proteins. Optimizing structural determination processes like X-ray crystallography will lead to an 
improvement of the ligands chosen as therapeutic medications. Increasing our understanding of 
ligand-receptor and receptor-receptor interactions using FRET or TR-FRET methods will continue 
to stimulate advances in drug-receptor interactions and drug development as a whole. Receptor 
internalization has also become a major topic in the tolerance of analgesic drugs like morphine and 
heroin. Better understanding of this receptor internalization could hold to key to the problem of 
addiction to detrimental narcotics.  
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